Johnson & Johnson announces collaboration with U.S. Department of Health and Human Services to fight influenza

Johnson & JohnsonJohnson & Johnson (NYSE: JNJ) announced that Janssen Research & Development LLC (Janssen) are collaborating with the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to develop a comprehensive portfolio of therapeutics and vaccines to protect communities in the event of an influenza pandemic and other infectious disease threats.

"Speeding the development of bio-preparedness countermeasures such as new therapies and vaccines requires that the private and public sectors join forces. No single government or company can do it alone," said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. "By bringing together the excellent scientific capabilities of Janssen with the world-class expertise of BARDA, this partnership enables us to accelerate our science and work towards having improved treatments for seasonal influenza and effective therapies in place should a pandemic arise."

Today, there are more than one billion cases of influenza globally each year, resulting in approximately five million cases of severe illness and up to half a million deaths.(1) The new collaboration has been formed as the centenary of the world's worst influenza pandemic approaches. In 1918, the "Spanish Flu" caused approximately 50 million deaths worldwide and experts predict that a pandemic could be far more devastating if it happened in today's globally mobile world.(2,3) New innovations for influenza are needed to address the shortcomings of current preventative and therapeutic options as well as concerns about the growing emergence of antiviral resistance.

Through this agreement, created under the U.S. Government's Other Transaction Authority (OTA), Janssen and BARDA, a component of ASPR, will invest equally to advance Janssen's extensive portfolio of investigational influenza medicines and vaccines throughout the duration of the collaboration. This portfolio based partnership and combined investment will ensure that vital research is made possible.

Assets within Janssen’s portfolio include JNJ-5806 (formerly AL-794), a potent small molecule inhibitor of influenza A and B viruses including strains with pandemic potential, and a "universal" vaccine candidate, which aims to protect against all influenza strains. Additional investigational products in the portfolio include therapeutic monoclonal antibodies, as well as new targets for emerging pathogens of potential public health concern.

BARDA began using OTAs to create innovative business partnerships with industry that ensure more products reach the market, and that the public has access to important countermeasures. If new medicines from this portfolio are approved, Janssen will work with relevant health stakeholders to ensure that these products are accessible.

This agreement further builds on the collaborations Janssen and BARDA have already established in influenza with pimodivir, our potential first-in-class inhibitor of the PB2 subunit of the influenza A polymerase complex, as well as in response to the 2014 Ebola outbreak in West Africa. This partnership provides a further portfolio of potential solutions to address the impact of influenza.

About Johnson & Johnson
Caring for the world... one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 132,500 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

About Janssen
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it.

1. World Health Organization. Influenza (seasonal). [Online]. Available at: http://www.who.int/mediacentre/factsheets/fs211/en/ Last accessed September 2017.
2. Taubenberger, J. et al. 1918 Influenza: The Mother of All Pandemics. Emerg Infect Dis. 2006;12(1):15-22. https://dx.doi.org/10.3201/eid1201.050979
3. The Next Pandemic: On the Front Lines Against Humankind’s Gravest Dangers. Khan A., Patrick W. 9781610395915. Public Affairs, 2016.

Most Popular Now

Forxiga receives positive EU CHMP opinion for the …

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a new indication for the marketing authorisation of Forxi...

Merck Granted U.S. Patent for novel combination of…

Merck, a leading science and technology company, today announced that it has been granted Patent No. US 10,193,695 by the United States Patent and Trademark Office (USPTO...

Pfizer receives positive CHMP opinion for Vizimpro…

Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending V...

US FDA grants Breakthrough Therapy Designation for…

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Ther...

Merck to expand US biopharmaceutical R&D facil…

Merck, a leading science and technology company, today announced a $70 million investment to expand its state of the art research and development (R&D) facility in Biller...

Amgen and UCB receive positive vote from FDA Advis…

Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) announced strong support from the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advis...

New pill can deliver insulin

An MIT-led research team has developed a drug capsule that could be used to deliver oral doses of insulin, potentially replacing the injections that people with type 2 di...

Pfizer and Lilly announce top-line results from se…

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.5 mg or 5 mg in patients...

Merck and Tencent announce collaboration on intell…

Merck, a leading science and technology company, signed a strategic collaboration agreement with Tencent, a leading provider of Internet value added services. The collabo...

Cannabinoid compounds may inhibit growth of colon …

Medical marijuana has gained attention in recent years for its potential to relieve pain and short-term anxiety and depression. Now, Penn State College of Medicine resear...

Researchers call for big data infrastructure to su…

Researchers from the George Washington University (GW), the U.S. Food and Drug Administration (FDA), and industry leaders published in PLOS Biology, describing a standard...

New computational method reduces risk of drug form…

One major factor that determines the efficacy of a drug is the structure that its molecules form in a solid state. Changed molecular structures can entail that pills stop...